The role of systemic inflammation in HIV-infected patients with moderate and severe psoriasis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Systemic inflammation is an important indicator of the immune response in chronic diseases. At the same time, it can act as a link between the mutual influence of various diseases among themselves. A convenient, simple indicator of the activity of systemic inflammation is the proportions of blood cells in a complete blood count. Evaluation of the indicators allows to estimate the intensity of inflammation and the mutual influence of chronic diseases. Objective. Evaluation of the role of systemic inflammation in the combination of HIV infection and psoriasis before and after the use of genetically engineered biological therapy (GIBT) and antiretroviral therapy (ART). Methods. 30 patients (10 patients with HIV infection+ psoriasis, 10 HIV-infected patients and 10 patients with psoriasis) were examined at the Infectious Clinical Hospital № 2 of the Moscow Healthcare Department, Polyclinic № 1 of the Administrative Department of the President of the Russian Federation and Pirogov Russian Gerontological Research and Clinical Center. PASI values in all patients corresponded to the moderate and severe dermatosis. HIV-infected patients began to receive ART, patients with psoriasis additionally received GIBT. PLR and NLR parameters were assessed in all patients; in HIV-infected patients, the viral load and the number of CD4+ lymphocytes were assessed before the start of treatment and 8 weeks after in dynamics. Results. Over 8 weeks, in HIV-infected patients with psoriasis the median PLR values shifted from 496.5 to 225.3 (P<0.05), in HIV-infected patients without psoriasis - from 406.3 to 348.6, respectively (P≤0.1). Median NLR values at week 0 in patients with HIV-infection + psoriasis was 2.3, at week 8 - 1.5; in the HIV-infected group - 2.2 and 1.5, respectively. Viral load of HIV RNA copies (log10) in patients with HIV+ psoriasis at week 0 was 5.8±1.6, and decreased to 3.1±0.7 at week 8 (P<0.05); in HIV-infected patients without psoriasis at week 0 - 5.7±1.1, and at week 8 - 4.2±0.9. The number of CD4+ cells/ml in partients with HIV+psoriasis was 307.5±12.7 and 336.3±14.2, respectively (P<0.05), in HIV-infected patients - 298.2±13.2 and 312.6±10.7. The Psoriasis Severity Scale in HIV-infected patients with psoriasis before treatment was 18.7±4.2, after 8 weeks - 5.3±2.1. Initially, joint pain according to the VAS was 71.2±6.3 points, after 8 weeks - 9.7±4.7. Conclusion. Systemic inflammation indicators, PLR and NLR, are directly related to PASI values in HIV-infected patients with psoriasis. A higher viral load and a decrease in the number of CD4+ lymphocytes correspond to increased PLR and NLR values. The combination of an IL-17 inhibitor (netakimab) and ART has a beneficial effect on indicators of systemic inflammation in HIV-infected patients with psoriasis.

Full Text

Restricted Access

About the authors

Evgeny Yu. Evdokimov

Central Research Institute of Epidemiology

Email: evdokimovevg@yandex.ru
Cand. Sci. (Med.), Researcher, Clinical Department Moscow, Russia

Zh. B Ponezheva

Central Research Institute of Epidemiology

Moscow, Russia

E. V Svechnikova

Polyclinic № 1 of the Administrative Department of the President of the Russian Federation; Novosibirsk State Medical University

Moscow, Russia; Novosibirsk, Russia

B. M Gruzdev

Infectious Clinical Hospital № 2 of the Moscow Healthcare Department

Moscow, Russia

A. D Meshkov

Russian Gerontological Research and Clinical Center Pirogov Russian National Research Medical University

Moscow, Russia

V. S Pykhtina

Russian Gerontological Research and Clinical Center Pirogov Russian National Research Medical University

Moscow, Russia

References

  1. Furman D., Campisi J., Verdin E., et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25:1822-32. doi: 10.1038/s41591-019-0675-0.
  2. Visser M.J.E., Venter C., Roberts T.J., et al. Psoriatic disease is associated with systemic inflammation, endothelial activation, and altered haemostatic function. Sci. Rep. 2021;11:13043. doi: 10.1038/s41598-021-90684-8
  3. Babu H., Ambikan A.T., Gabriel E.E., et al. Systemic Inflammation and the Increased Risk of Inflamm-Aging and Age-Associated Diseases in People Living With HIV on Long Term Suppressive Antiretroviral Therapy. Front Immunol. 2019;10:1965. doi: 10.3389/fimmu.2019.01965.
  4. Takeda T, Morita H., Saito H., et al. Recent advances in understanding the roles of blood platelets in the pathogenesis of allergic inflammation and bronchial asthma. Allergol Int. 33. doi: 10.1016/j.alit.2017.11.008.
  5. Wang W.M., Wu C., Gao Y.M., et al. Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and other hematological parameters in psoriasis patients. BMC. Immunol. 2021;22:64. doi: 10.1186/s12865-021-00454-4.
  6. Rossouw T.M., Feldman C. Editorial: The Role of Platelet Activation in the Pathophysiology of HIV, Tuberculosis and Pneumococcal Disease. Front. Immunol. 2021;12:737016. Doi: 10.3389/ fimmu.2021.737016.
  7. Hu S.S., Yu H.S., Yen F.L. et al. Neutrophil extracellular trap formation is increased in psoriasis and induces human ß-defensin-2 production in epidermal keratinocytes. Sci. Rep. 2016;6:31119. doi: 10.1038/srep31119.
  8. Hensley-McBain T., Klatt N.R. The Dual Role of Neutrophils in HIV Infection. Curr. HIV/AIDS Rep. 2018;15(1):1-10. doi: 10.1007/s11904-018-0370-7.
  9. Moodley M., Moodley J., Naicker T The Role of Neutrophils and Their Extracellular Traps in the Synergy of Pre-eclampsia and HIV Infection. Curr Hypertens Rep. 2020;22(6):41. doi: 10.1007/s11906-020-01047-z.
  10. Blauvelt A., Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379-90. doi: 10.1007/s12016-018-8702-3.
  11. Zhu Z., Li T., Chen J., et al. The Role of Inflammation and Immune Activation on Circulating Endothelial Progenitor Cells in Chronic HIV Infection. Front. Immunol. 2021;12:663412. doi: 10.3389/fimmu.2021.663412.
  12. Alpalhao M., Borges-Costa J., Filipe P. Psoriasis in HIV infection: an update.Int. J. STD AIDS. 2019;30(6):596-604. doi: 10.1177/095646241982 7673.
  13. Pangilinan M.C., Sermswan G.P., Asawanonda P. Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis. Case Rep. Dermatol. 2020;12:132-37. doi: 10.1159/000508781.
  14. van Gemst J.J., Kouwenberg M., Rops A.L.W.M.M., et al. Differential binding of chemokines CXCL1, CXCL2 and CCL2 to mouse glomerular endothelial cells reveals specificity for distinct heparan sulfate domains. PLoS One. 2018;13(9):e0201560. doi: 10.1371/journal.pone.0201560.
  15. Kuwabara T, Ishikawa F., Kondo M., Kakiuchi T. The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases. Mediators Inflamm. 2017;2017:3908061. doi: 10.1155/2017/3908061.
  16. Liu L., Liu Y., Yan X., et al. The role of granulocyte colony stimulating factor in breast cancer development: A review. Mol. Med. Rep. 2020;21(5):2019-29. doi: 10.3892/mmr.2020.11017.
  17. IL-17A reprograms intestinal epithelial cells to facilitate HIV-1 replication and outgrowth in CD4+ T cells. doi: 10.1016/j.isci.2021.103225.
  18. Blauvelt A., Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379-90. doi: 10.1007/s12016-018-8702-3.
  19. Qian F., Yan Y., Huang J., et al. Use of ixekizumab in an HIV-positive patient with psoriatic arthritis.Int. J. STD AIDS. 2022;33(5):519-21. doi: 10.1177/09564624221076289.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies